PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27881007-9 2017 The DiOC6 (3) negative cell rate was increased and p65 of NF-kappaB, XIAP and survivin expression was reduced by the combination treatment.In summary, EGCG sensitizes NPC cells to TRAIL-mediated apoptosis via modulation of extrinsic and intrinsic apoptotic pathways and inhibition of NF-kappaB activation. epigallocatechin gallate 151-155 RELA proto-oncogene, NF-kB subunit Homo sapiens 51-54 33038311-3 2020 We found that EGCG inhibits NF-kappaB-p65 transcriptional activity, by preventing NF-kappaB-p65 binding to kappaBs in normal human bronchial epithelial cells. epigallocatechin gallate 14-18 RELA proto-oncogene, NF-kB subunit Homo sapiens 38-41 33038311-3 2020 We found that EGCG inhibits NF-kappaB-p65 transcriptional activity, by preventing NF-kappaB-p65 binding to kappaBs in normal human bronchial epithelial cells. epigallocatechin gallate 14-18 RELA proto-oncogene, NF-kB subunit Homo sapiens 28-41 33038311-4 2020 We also analyzed the chemical mechanism by which EGCG binds directly to NF-kappaB-p65, and found that it involves covalent reaction via enones within EGCG ring structures, as the oxidizer diamide, which prevents 1, 4-addition reactions, blocked adduct-forming reaction of biotinylated EGCG with NF-kappaB-p65. epigallocatechin gallate 49-53 RELA proto-oncogene, NF-kB subunit Homo sapiens 72-85 33038311-4 2020 We also analyzed the chemical mechanism by which EGCG binds directly to NF-kappaB-p65, and found that it involves covalent reaction via enones within EGCG ring structures, as the oxidizer diamide, which prevents 1, 4-addition reactions, blocked adduct-forming reaction of biotinylated EGCG with NF-kappaB-p65. epigallocatechin gallate 49-53 RELA proto-oncogene, NF-kB subunit Homo sapiens 295-308 33907248-8 2021 EGCG also decreased expression of substrate oncoproteins for PIN1 (including cyclin D1, NF-kappaB p65, c-MYC, and AKT) and 67 kDa laminin receptor (67LR) in the bone marrow cells. epigallocatechin gallate 0-4 RELA proto-oncogene, NF-kB subunit Homo sapiens 88-101 33038311-6 2020 Furthermore, such covalent binding reflected irreversible reaction of EGCG with sulfhydryls of NF-kappaB-p65, as it was inhibited by glutathione but not reversible by it. epigallocatechin gallate 70-74 RELA proto-oncogene, NF-kB subunit Homo sapiens 95-108 33038311-7 2020 We identified the reactive sulfhydryl moiety as that of cysteine, as S-carboxymethylation to block cysteine sulfhydryls prevented NF-kappaB-p65-Cys-alkylation reaction with EGCG. epigallocatechin gallate 173-177 RELA proto-oncogene, NF-kB subunit Homo sapiens 130-143 33038311-8 2020 We also tested if EGCG can inhibit NF-kappaB-p65 binding to DNA within the nucleus, after its phosphorylation and translocation (activation). epigallocatechin gallate 18-22 RELA proto-oncogene, NF-kB subunit Homo sapiens 45-48 33038311-9 2020 EGCG did not alter intranuclear phosphorylation levels of NF-kappaB-p65, but strongly repressed DNA-binding ability of activated NF-kappaB-p65, indicating that EGCG inhibits NF-kappaB-p65 DNA binding activity even without altering NF-kappaB-p65 phosphorylation or expression. epigallocatechin gallate 0-4 RELA proto-oncogene, NF-kB subunit Homo sapiens 129-142 33038311-9 2020 EGCG did not alter intranuclear phosphorylation levels of NF-kappaB-p65, but strongly repressed DNA-binding ability of activated NF-kappaB-p65, indicating that EGCG inhibits NF-kappaB-p65 DNA binding activity even without altering NF-kappaB-p65 phosphorylation or expression. epigallocatechin gallate 0-4 RELA proto-oncogene, NF-kB subunit Homo sapiens 129-142 33038311-9 2020 EGCG did not alter intranuclear phosphorylation levels of NF-kappaB-p65, but strongly repressed DNA-binding ability of activated NF-kappaB-p65, indicating that EGCG inhibits NF-kappaB-p65 DNA binding activity even without altering NF-kappaB-p65 phosphorylation or expression. epigallocatechin gallate 0-4 RELA proto-oncogene, NF-kB subunit Homo sapiens 129-142 33038311-9 2020 EGCG did not alter intranuclear phosphorylation levels of NF-kappaB-p65, but strongly repressed DNA-binding ability of activated NF-kappaB-p65, indicating that EGCG inhibits NF-kappaB-p65 DNA binding activity even without altering NF-kappaB-p65 phosphorylation or expression. epigallocatechin gallate 160-164 RELA proto-oncogene, NF-kB subunit Homo sapiens 129-142 33038311-9 2020 EGCG did not alter intranuclear phosphorylation levels of NF-kappaB-p65, but strongly repressed DNA-binding ability of activated NF-kappaB-p65, indicating that EGCG inhibits NF-kappaB-p65 DNA binding activity even without altering NF-kappaB-p65 phosphorylation or expression. epigallocatechin gallate 160-164 RELA proto-oncogene, NF-kB subunit Homo sapiens 129-142 33038311-9 2020 EGCG did not alter intranuclear phosphorylation levels of NF-kappaB-p65, but strongly repressed DNA-binding ability of activated NF-kappaB-p65, indicating that EGCG inhibits NF-kappaB-p65 DNA binding activity even without altering NF-kappaB-p65 phosphorylation or expression. epigallocatechin gallate 160-164 RELA proto-oncogene, NF-kB subunit Homo sapiens 129-142 33038311-10 2020 These findings thus reveal a novel mechanism by which EGCG inhibits transcriptional activity of NF-kappaB-p65, that may potentially contribute to anti-inflammatory and health-promoting effects of EGCG and consumption of tea. epigallocatechin gallate 54-58 RELA proto-oncogene, NF-kB subunit Homo sapiens 96-109 33038311-10 2020 These findings thus reveal a novel mechanism by which EGCG inhibits transcriptional activity of NF-kappaB-p65, that may potentially contribute to anti-inflammatory and health-promoting effects of EGCG and consumption of tea. epigallocatechin gallate 196-200 RELA proto-oncogene, NF-kB subunit Homo sapiens 96-109 33074673-4 2020 Two representative EPSFs (R-EGCG-cThea and S-EGCG-cThea) possess potential anti-inflammatory properties by suppressing the expression, phosphorylation, and nuclear translocation of nuclear factor kappa-B (NF-kappaB) p65 in lipopolysaccharide-stimulated macrophages based on western blotting and immunofluorescence results. epigallocatechin gallate 43-49 RELA proto-oncogene, NF-kB subunit Homo sapiens 216-219 31999881-7 2020 Expression of p-p65 protein in HDPCs treated with ECG, EGCG or an NF-kappaB inhibitor (Bay11-7082) was lower than that in HDPCs treated with lipopolysaccharide, data that were consistent with the location of p65 protein according to immunofluorescence staining. epigallocatechin gallate 55-59 RELA proto-oncogene, NF-kB subunit Homo sapiens 16-19 28367625-5 2017 Moreover, EGCG stimulated translocation of the p50 and p65 subunits of NF-kappaB and enhanced NF-kappaB DNA-binding activity, thus suppressing SR-A promoter activity. epigallocatechin gallate 10-14 RELA proto-oncogene, NF-kB subunit Homo sapiens 55-58 25487615-9 2015 NF-kappaB p65 is a novel therapeutic target in NPCSCs, and the inhibition of activated NF-kappaB p65 in CSCs by EGCG may offer an effective treatment for NPC. epigallocatechin gallate 112-116 RELA proto-oncogene, NF-kB subunit Homo sapiens 97-100 27791197-5 2016 Additionally, the phosphorylation of IkappaBalpha, p-TAK1 expression are decreased and the nuclear translocation of p65 and p50 is blocked by treatment with EGCG, leading to inactivation of the NF-kappaB pathway. epigallocatechin gallate 157-161 RELA proto-oncogene, NF-kB subunit Homo sapiens 116-119 26878794-8 2016 This inhibitory effect by EGCG correlated with abolished nuclear import of p65, decreased chromatin binding of p65 and p300, as well as increased chromatin binding of HDAC 1/2. epigallocatechin gallate 26-30 RELA proto-oncogene, NF-kB subunit Homo sapiens 75-78 26878794-8 2016 This inhibitory effect by EGCG correlated with abolished nuclear import of p65, decreased chromatin binding of p65 and p300, as well as increased chromatin binding of HDAC 1/2. epigallocatechin gallate 26-30 RELA proto-oncogene, NF-kB subunit Homo sapiens 111-114 25487615-0 2015 (-)-Epigallocatechin-3-gallate inhibits nasopharyngeal cancer stem cell self-renewal and migration and reverses the epithelial-mesenchymal transition via NF-kappaB p65 inactivation. epigallocatechin gallate 0-30 RELA proto-oncogene, NF-kB subunit Homo sapiens 164-167 25487615-3 2015 Epigallocatechin-3-gallate (EGCG) inhibits cancer progression by attenuating NF-kappaB p65 activity, which is upregulated in CSCs and plays an important role in epithelial-mesenchymal transition (EMT). epigallocatechin gallate 0-26 RELA proto-oncogene, NF-kB subunit Homo sapiens 87-90 25487615-3 2015 Epigallocatechin-3-gallate (EGCG) inhibits cancer progression by attenuating NF-kappaB p65 activity, which is upregulated in CSCs and plays an important role in epithelial-mesenchymal transition (EMT). epigallocatechin gallate 28-32 RELA proto-oncogene, NF-kB subunit Homo sapiens 87-90 25487615-8 2015 Moreover, EGCG inhibited NF-kappaB p65 activity by modulating the cellular localization of p65 and decreasing the transcriptional regulation of NF-kappaB p65 on Twist1 expression. epigallocatechin gallate 10-14 RELA proto-oncogene, NF-kB subunit Homo sapiens 35-38 25487615-8 2015 Moreover, EGCG inhibited NF-kappaB p65 activity by modulating the cellular localization of p65 and decreasing the transcriptional regulation of NF-kappaB p65 on Twist1 expression. epigallocatechin gallate 10-14 RELA proto-oncogene, NF-kB subunit Homo sapiens 91-94 25487615-8 2015 Moreover, EGCG inhibited NF-kappaB p65 activity by modulating the cellular localization of p65 and decreasing the transcriptional regulation of NF-kappaB p65 on Twist1 expression. epigallocatechin gallate 10-14 RELA proto-oncogene, NF-kB subunit Homo sapiens 91-94 24269954-9 2014 The effect of EGCG may be related to the inhibition of nuclear factor-kappaB (NF-kappaB) and mitogen-activated protein kinase (MAPK) signaling pathways by down-regulation of p-IkappaBalpha, p65, p-p65, p-p38, p-ERK1/2, and p-AKT. epigallocatechin gallate 14-18 RELA proto-oncogene, NF-kB subunit Homo sapiens 190-193 25988128-8 2014 EGCG improved efficacy of cisplatin treatment in HeLa cells by regulating NFkappaB p65, COX-2, p-Akt, and p-mTOR pathways, whereas it increased the expression levels of Nrf2/HO-1 in combined therapy. epigallocatechin gallate 0-4 RELA proto-oncogene, NF-kB subunit Homo sapiens 83-86 25057854-5 2014 Quercetin, luteolin, and epigallocatechin gallate suppressed nuclear factor-kappaB activation by inhibition of p65 phosphorylation with beneficial regulation of adipokine expression, whereas these actions were diminished by coincubation with compound C. The sirtuin 1 inhibitor nicotinamide attenuated the effects of luteolin and EGCG on p65 phosphorylation and adipokine expression without any influence on the activity of quercetin. epigallocatechin gallate 25-49 RELA proto-oncogene, NF-kB subunit Homo sapiens 111-114 25057854-5 2014 Quercetin, luteolin, and epigallocatechin gallate suppressed nuclear factor-kappaB activation by inhibition of p65 phosphorylation with beneficial regulation of adipokine expression, whereas these actions were diminished by coincubation with compound C. The sirtuin 1 inhibitor nicotinamide attenuated the effects of luteolin and EGCG on p65 phosphorylation and adipokine expression without any influence on the activity of quercetin. epigallocatechin gallate 25-49 RELA proto-oncogene, NF-kB subunit Homo sapiens 338-341 24269954-9 2014 The effect of EGCG may be related to the inhibition of nuclear factor-kappaB (NF-kappaB) and mitogen-activated protein kinase (MAPK) signaling pathways by down-regulation of p-IkappaBalpha, p65, p-p65, p-p38, p-ERK1/2, and p-AKT. epigallocatechin gallate 14-18 RELA proto-oncogene, NF-kB subunit Homo sapiens 197-200 20011976-6 2009 EGCG inhibits the expression of the P65 mRNA and P65/pP65 protein, meanwhile it downregulates pIkappaBalpha expression and upregulates IkappaBalpha expression. epigallocatechin gallate 0-4 RELA proto-oncogene, NF-kB subunit Homo sapiens 36-39 22843790-9 2012 Electrophoretic mobility shift assay revealed that the OSM-enhanced NF-kappaB/DNA binding was reduced by EGCG, possibly through abrogating nucleus localization of p65 and p50. epigallocatechin gallate 105-109 RELA proto-oncogene, NF-kB subunit Homo sapiens 163-166 20963498-7 2011 Moreover, expression of phosphorylated NF-kappaB/p65 in HT-1080 cells was inhibited by EGCG treatment in a dose-dependent manner, while that of unphosphorylated NF-kappaB/p65 remained unaffected. epigallocatechin gallate 87-91 RELA proto-oncogene, NF-kB subunit Homo sapiens 49-52 20963498-7 2011 Moreover, expression of phosphorylated NF-kappaB/p65 in HT-1080 cells was inhibited by EGCG treatment in a dose-dependent manner, while that of unphosphorylated NF-kappaB/p65 remained unaffected. epigallocatechin gallate 87-91 RELA proto-oncogene, NF-kB subunit Homo sapiens 171-174 22022384-8 2011 Moreover, EGCG inhibited the activation of NF-kappaB/p65, an upstream regulator of COX-2, in A375 melanoma cells, and treatment of cells with caffeic acid phenethyl ester, an inhibitor of NF-kappaB, also inhibited cell migration. epigallocatechin gallate 10-14 RELA proto-oncogene, NF-kB subunit Homo sapiens 53-56 20011976-6 2009 EGCG inhibits the expression of the P65 mRNA and P65/pP65 protein, meanwhile it downregulates pIkappaBalpha expression and upregulates IkappaBalpha expression. epigallocatechin gallate 0-4 RELA proto-oncogene, NF-kB subunit Homo sapiens 49-52 14676829-5 2004 Treatment of A431 cells with EGCG (10-40 microg/ml) resulted in dose-dependent inhibition of NF-kappa B/p65, induction of DNA breaks, cleavage of poly(ADP-ribose) polymerase (PARP) and morphological changes consistent with apoptosis. epigallocatechin gallate 29-33 RELA proto-oncogene, NF-kB subunit Homo sapiens 104-107 15113942-7 2004 In addition, EGCG inhibited phosphorylation of the p65 subunit of NF-kappa B. epigallocatechin gallate 13-17 RELA proto-oncogene, NF-kB subunit Homo sapiens 51-76 19502799-8 2009 Further, the anti-proliferative effects of EGCG and/or IFN were accompanied with an increase in Fas protein levels and a decrease in nuclear factor NFkappaB/p65 in the nucleus as well as NFkappaB promoter activity. epigallocatechin gallate 43-47 RELA proto-oncogene, NF-kB subunit Homo sapiens 157-160 19147572-0 2009 Epigallocatechin-3-gallate, a histone acetyltransferase inhibitor, inhibits EBV-induced B lymphocyte transformation via suppression of RelA acetylation. epigallocatechin gallate 0-26 RELA proto-oncogene, NF-kB subunit Homo sapiens 135-139 19147572-3 2009 At a dose of 100 micromol/L, EGCG abrogates p300-induced p65 acetylation in vitro and in vivo, increases the level of cytosolic IkappaBalpha, and suppresses tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation. epigallocatechin gallate 29-33 RELA proto-oncogene, NF-kB subunit Homo sapiens 57-60 19147572-4 2009 We also showed that EGCG prevents TNFalpha-induced p65 translocation to the nucleus, confirming that hyperacetylation is critical for NF-kappaB translocation as well as activity. epigallocatechin gallate 20-24 RELA proto-oncogene, NF-kB subunit Homo sapiens 51-54 19147572-5 2009 Furthermore, EGCG treatment inhibited the acetylation of p65 and the expression of NF-kappaB target genes in response to diverse stimuli. epigallocatechin gallate 13-17 RELA proto-oncogene, NF-kB subunit Homo sapiens 57-60 16862172-6 2007 Pretreatment of NHBE cells with EGCG suppressed CSC-induced phosphorylation of IkappaBalpha, and activation and nuclear translocation of NF-kappaB/p65. epigallocatechin gallate 32-36 RELA proto-oncogene, NF-kB subunit Homo sapiens 147-150 15147726-4 2004 And then nuclear translocation of NF-kappaB (p65) after the EGCG treatment was analyzed by immunofluorescence and western blotting. epigallocatechin gallate 60-64 RELA proto-oncogene, NF-kB subunit Homo sapiens 45-48 15147726-8 2004 EGCG also suppressed the nuclear translocation of NF-kappaB (p65) and IkappaBalpha phosphorylation. epigallocatechin gallate 0-4 RELA proto-oncogene, NF-kB subunit Homo sapiens 61-64 14676829-7 2004 EGCG-mediated caspase activation induces proteolytic cleavage of NF-kappa B/p65 subunit, leading to the loss of transactivation domains, and driving the cells towards apoptosis. epigallocatechin gallate 0-4 RELA proto-oncogene, NF-kB subunit Homo sapiens 76-79 14676829-9 2004 Further, pretreatment of cells with Z-VAD-FMK was found to suppress the cleavage of NF-kappa B/p65 subunit, thereby increasing nuclear translocation, DNA binding and transcriptional activity, thus protecting the cells from EGCG-induced apoptosis. epigallocatechin gallate 223-227 RELA proto-oncogene, NF-kB subunit Homo sapiens 95-98 12592390-8 2003 Employing immunoblot analysis, enzyme-linked immunosorbent assay, and gel shift assay, we demonstrate that EGCG treatment of the cells resulted in a significant dose- and time-dependent inhibition of UVB-mediated activation and nuclear translocation of a NF-kappaB/p65. epigallocatechin gallate 107-111 RELA proto-oncogene, NF-kB subunit Homo sapiens 265-268